Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer.
;
Isabel
dos Santos Silva
;
Julian
Peto
;
Stefan
Nickels
;
Dieter
Flesch-Janys
;
Hoda
Anton-Culver
;
Argyrios
Ziogas
;
Elinor
Sawyer
;
Ian
Tomlinson
;
Michael
Kerin
;
Nicola
Miller
;
Marjanka K
Schmidt
;
Annegien
Broeks
;
Laura J
Van 't Veer
;
Rob AEM
Tollenaar
;
Paul DP
Pharoah
;
Alison M
Dunning
;
Karen A
Pooley
;
Frederik
Marme
;
Andreas
Schneeweiss
;
Christof
Sohn
;
Barbara
Burwinkel
;
Anna
Jakubowska
;
Jan
Lubinski
;
Katarzyna
Jaworska
;
Katarzyna
Durda
;
Daehee
Kang
;
Keun-Young
Yoo
;
Dong-Young
Noh
;
Sei-Hyun
Ahn
;
David J
Hunter
;
Susan E
Hankinson
;
Peter
Kraft
;
Sara
Lindstrom
;
Xiaoqing
Chen
;
Jonathan
Beesley
;
Ute
Hamann
;
Volker
Harth
;
Christina
Justenhoven
;
GENICA Network
;
Robert
Winqvist
;
Katri
Pylkäs
;
Arja
Jukkola-Vuorinen
;
Mervi
Grip
;
Maartje
Hooning
;
Antoinette
Hollestelle
;
Rogier A
Oldenburg
;
Madeleine
Tilanus-Linthorst
;
Elza
Khusnutdinova
;
Marina
Bermisheva
;
Darya
Prokofieva
;
Albina
Farahtdinova
;
Janet E
Olson
;
Xianshu
Wang
;
Manjeet K
Humphreys
;
Qin
Wang
;
Georgia
Chenevix-Trench
;
kConFab Investigators
;
AOCS Group
;
Douglas F
Easton
;
(2011)
Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer.
Cancer epidemiology, biomarkers & prevention, 20 (10).
pp. 2222-2231.
ISSN 1055-9965
DOI: 10.1158/1055-9965.EPI-11-0569
BACKGROUND: The single-nucleotide polymorphism (SNP) 5p12-rs10941679 has been found to be associated with risk of breast cancer, particularly estrogen receptor (ER)-positive disease. We aimed to further explore this association overall, and by tumor histopathology, in the Breast Cancer Association Consortium. METHODS: Data were combined from 37 studies, including 40,972 invasive cases, 1,398 cases of ductal carcinoma in situ (DCIS), and 46,334 controls, all of white European ancestry, as well as 3,007 invasive cases and 2,337 controls of Asian ancestry. Associations overall and by tumor invasiveness and histopathology were assessed using logistic regression. RESULTS: For white Europeans, the per-allele OR associated with 5p12-rs10941679 was 1.11 (95% CI = 1.08-1.14, P = 7 × 10(-18)) for invasive breast cancer and 1.10 (95% CI = 1.01-1.21, P = 0.03) for DCIS. For Asian women, the estimated OR for invasive disease was similar (OR = 1.07, 95%CI = 0.99-1.15, P = 0.09). Further analyses suggested that the association in white Europeans was largely limited to progesterone receptor (PR)-positive disease (per-allele OR = 1.16, 95% CI = 1.12-1.20, P = 1 × 10(-18) vs. OR = 1.03, 95% CI = 0.99-1.07, P = 0.2 for PR-negative disease; P(heterogeneity) = 2 × 10(-7)); heterogeneity by ER status was not observed (P = 0.2) once PR status was accounted for. The association was also stronger for lower grade tumors [per-allele OR (95% CI) = 1.20 (1.14-1.25), 1.13 (1.09-1.16), and 1.04 (0.99-1.08) for grade 1, 2, and 3/4, respectively; P(trend) = 5 × 10(-7)]. CONCLUSION: 5p12 is a breast cancer susceptibility locus for PR-positive, lower grade breast cancer. IMPACT: Multicenter fine-mapping studies of this region are needed as a first step to identifying the causal variant or variants.